公开(公告)号：AU2004292393A1

公开(公告)日：2005-06-09

申请号：AU2004292393

申请日：2004-11-16

Applicant: CELLTECH R&D LTD

Inventor： ROBINSON MARTYN KIM ,  CHRISTIE MARK IAN ,  MEAD RICHARD JAMES ,  RAPECKI STEPHEN EDWARD

IPC: C07K16/24 ,  A61K47/48

公开(公告)号：CA2544920A1

公开(公告)日：2005-06-09

申请号：CA2544920

申请日：2004-11-16

Applicant: CELLTECH R&D LTD

Inventor： RAPECKI STEPHEN EDWARD ,  MEAD RICHARD JAMES ,  ROBINSON MARTYN KIM ,  CHRISTIE MARK IAN

IPC: A61K39/395 ,  A61K47/48 ,  A61P37/00 ,  C07K16/24

公开(公告)号：CA2544920C

公开(公告)日：2012-09-11

申请号：CA2544920

申请日：2004-11-16

Applicant: CELLTECH R&D LTD

Inventor： CHRISTIE MARK IAN ,  MEAD RICHARD JAMES ,  ROBINSON MARTYN KIM ,  RAPECKI STEPHEN EDWARD

IPC: A61K39/395 ,  A61K47/48 ,  A61P37/00 ,  C07K16/24

Abstract: The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity.

公开(公告)号：CA2473089A1

公开(公告)日：2003-08-28

申请号：CA2473089

申请日：2003-02-19

Applicant: CELLTECH R&D LTD

Inventor： MEISSNER JOHANNES WILHELM GEOR ,  WATSON ROBERT JOHN ,  OWEN DAVID ALAN ,  CHRISTIE MARK IAN

IPC: A61K31/4468 ,  A61P1/04 ,  A61P11/06 ,  A61P17/00 ,  A61P19/02 ,  A61P25/00 ,  A61P27/16 ,  A61P29/00 ,  A61P31/12 ,  A61P33/00 ,  A61P37/02 ,  A61P37/06 ,  C07D211/58 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  A61K31/17 ,  C07C275/28 ,  A61K31/453 ,  A61K31/4535 ,  A61K31/4709

Abstract: Cyclic amino derivatives of formula (1) are described: (1) wherein: m and n, which may be the same or different, is each zero or the integer 1 or 2; AIk3 ~ is a covalent bond or a straight or branched C~1-6 alkylene chain; R1~ and R2~, which may be the same or different, is each a hydrogen atom or a straig ht or branched C~1-6 alkyl group; D is an optionally substituted aromatic or heteroaromatic group; E is an optionally substituted C~7-10 cycloalkyl, C~7- 10 cycloalkenyl or C~7-10 polycycloaliphatic group; and the salts, solvates, hydrates, tautomers or N-oxides thereof. The compounds are potent and selective modulators of the interaction between CXCR3 and its chemokine ligands and are thus of use in medicine, for example in the prevention or treatment of conditions involving inappropriate T-cell trafficking such as certain inflammatory, autoimmune and immunoregulatory disorders as described hereinafter.

公开(公告)号：AU2003208423A1

公开(公告)日：2003-09-09

申请号：AU2003208423

申请日：2003-02-19

Applicant: CELLTECH R&D LTD

Inventor： WATSON ROBERT JOHN ,  MEISSNER JOHANNES WILHELM GEOR ,  CHRISTIE MARK IAN ,  OWEN DAVID ALAN

IPC: A61K31/4468 ,  A61P1/04 ,  A61P11/06 ,  A61P17/00 ,  A61P19/02 ,  A61P25/00 ,  A61P27/16 ,  A61P29/00 ,  A61P31/12 ,  A61P33/00 ,  A61P37/02 ,  A61P37/06 ,  C07D211/58 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  A61K31/453 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/17 ,  C07C275/28

Abstract: Cyclic amino derivatives of formula (1) are described: (1) wherein: m and n, which may be the same or different, is each zero or the integer 1 or 2; Alk 3 is a covalent bond or a straight or branched C 1-6 alkylene chain; R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a straight or branched C 1-6 alkyl group; D is an optionally substituted aromatic or heteroaromatic group; E is an optionally substituted C 7-10 cycloalkyl, C 7-10 cycloalkenyl or C 7-10 polycycloaliphatic group; and the salts, solvates, hydrates, tautomers or N-oxides thereof. The compounds are potent and selective modulators of the interaction between CXCR3 and its chemokine ligands and are thus of use in medicine, for example in the prevention or treatment of conditions involving inappropriate T-cell trafficking such as certain inflammatory, autoimmune and immunoregulatory disorders as described hereinafter.